O
CELC icon

OrbiMed’s Celcuity CELC Stock Holding History

OrbiMed’s Portfolio CELC Stock Details CELC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-85,664
Closed -$8.54M – 115
2025
Q4 		$8.54M Buy
85,664
+1,644
+2% +$135K 0.17% 84
2025
Q3 		$4.15M Buy
+84,020
New +$3.36M 0.1% 92

Other funds holding CELC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

OrbiMed's CELC Position: Q1 2026 in Review

OrbiMed sold out of Celcuity (CELC) in Q1 2026, closing a stake of 85,664 shares — an estimated $8.54M sold.

OrbiMed first reported a position in CELC in Q3 2025 and held it in 2 quarters. The position peaked at $8.54M in Q4 2025. 276 funds tracked by Wall St. Rank hold CELC as of Q1 2026.

  • OrbiMed reported no remaining Celcuity position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 85,664 Celcuity shares in Q1 2026, an estimated $8.54M.
  • OrbiMed first reported a position in Celcuity in Q3 2025 and held it in 2 quarters.
  • OrbiMed's Celcuity position peaked at $8.54M in Q4 2025.
  • 276 funds tracked by Wall St. Rank held Celcuity as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.